AstraZeneca To Buy China Drug Makers For Local Focus On Generics
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca’s global-production CEO says the firm plans to acquire smaller Chinese drug makers and introduce more generic versions of its innovative drugs as part of a strategy to take advantage of the fast-growing market.